Prediction of steady-state volume of distribution of acidic drugs by quantitative structure-pharmacokinetics relationships.

The volume of distribution (VD) is one of the most important pharmacokinetic parameters of drugs. The present study employs quantitative structure-pharmacokinetics relationships (QSPkR) to derive models for VD prediction of acidic drugs. The steady-state volume of distribution (VD(ss)) values of 132 acidic drugs were collected, the chemical structures were described by 178 molecular descriptors, and QSPkR models were derived after variable selection by genetic algorithm and stepwise regression. Models were validated by cross-validation procedures and external test set. According to the molecular descriptors selected as the most predictive for VD(ss), the presence of seven- and nine-member cycles, atom type P(5+), SH groups, and large nonionized substituents increase the VD(ss), whereas atom types S(2+) and S(4+) and polar ionized substituents decrease it. Cross-validation and external validation studies on the QSPkR models derived in the present study showed good predictive ability with mean fold error values ranging from 1.58 (cross-validation) to 2.25 (external validation). The model performance is comparable to more complicated methods requiring in vitro or in vivo experiments and superior to the existing QSPkR models concerning acidic drugs. Apart from the prediction of VD in human, present models are also useful as a curator of available pharmacokinetic databases.

[1]  Franco Lombardo,et al.  Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. , 2004, Journal of medicinal chemistry.

[2]  Jin Sun,et al.  Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data. , 2009, European journal of medicinal chemistry.

[3]  R. Rondanelli,et al.  A Clinical and Pharmacokinetic Study , 1983 .

[4]  W. Shelver,et al.  Quantitative structure-pharmacokinetic relationships (QSPR) of beta blockers derived using neural networks. , 1995, Journal of pharmaceutical sciences.

[5]  U. Fagerholm,et al.  Prediction of human pharmacokinetics – evaluation of methods for prediction of volume of distribution , 2007, The Journal of pharmacy and pharmacology.

[6]  E. Li,et al.  Zoledronic acid: a new parenteral bisphosphonate. , 2003, Clinical therapeutics.

[7]  Donald E Mager,et al.  Quantitative structure-pharmacokinetic/pharmacodynamic relationships. , 2006, Advanced drug delivery reviews.

[8]  Snezana Agatonovic-Kustrin,et al.  Multiple pharmacokinetic parameter prediction for a series of cephalosporins. , 2003, Journal of pharmaceutical sciences.

[9]  Malcolm Rowland,et al.  Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications , 1980 .

[10]  T. Wilson,et al.  Ridogrel: An Antiplatelet Agent with Antihypertensive Properties , 2006 .

[11]  Panos Macheras,et al.  Multivariate Statistics of Disposition Pharmacokinetic Parameters for Structurally Unrelated Drugs Used in Therapeutics , 2002, Pharmaceutical Research.

[12]  J. V. Turner,et al.  Pharmacokinetic parameter prediction from drug structure using artificial neural networks. , 2004, International journal of pharmaceutics.

[13]  P. Newton,et al.  The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria , 2006, European Journal of Clinical Pharmacology.

[14]  Qigui Li,et al.  The evaluation of radiolabeled artesunate on tissue distribution in rats and protein binding in humans. , 2006, The American journal of tropical medicine and hygiene.

[15]  M. Orme,et al.  The interaction between indomethacin and probenecid; A clinical and pharmacokinetic study , 1978, Clinical pharmacology and therapeutics.

[16]  N. Davies,et al.  Choosing the Right Nonsteroidal Anti-Inflammatory Drug for the Right Patient , 2000, Clinical pharmacokinetics.

[17]  Taravat Ghafourian,et al.  QSPR models for the prediction of apparent volume of distribution. , 2006, International journal of pharmaceutics.

[18]  A. Schweitzer,et al.  Biodistribution and Plasma Protein Binding of Zoledronic Acid , 2008, Drug Metabolism and Disposition.

[19]  Y. Yano,et al.  Prediction of human pharmacokinetics from animal data and molecular structural parameters using multivariate regression analysis: volume of distribution at steady state , 2003, The Journal of pharmacy and pharmacology.

[20]  R. Slaughter,et al.  The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics , 2004, European Journal of Clinical Pharmacology.

[21]  Franco Lombardo,et al.  Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. , 2002, Journal of medicinal chemistry.

[22]  Lemont B. Kier,et al.  Intermolecular Accessibility: The Meaning of Molecular Connectivity , 2000, J. Chem. Inf. Comput. Sci..

[23]  A Review of the Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin , 2002, Journal of clinical pharmacology.

[24]  J. Freidman,et al.  Multivariate adaptive regression splines , 1991 .

[25]  W. Jusko,et al.  Quantitative structure-pharmacokinetic/pharmacodynamic relationships of corticosteroids in man. , 2002, Journal of pharmaceutical sciences.

[26]  D. Tashkin Multiple dose regimens. Impact on compliance. , 1995, Chest.

[27]  K. Lees,et al.  Pharmacokinetics of a glycine site antagonist (gavestinel) following multiple dosing in patients with acute stroke , 2000, European Journal of Clinical Pharmacology.

[28]  R. Boggia,et al.  Genetic algorithms as a strategy for feature selection , 1992 .

[29]  U. Kragh-Hansen,et al.  Complexes of aliphatic sulfates and human-serum albumin studied by 13C nuclear-magnetic-resonance spectroscopy. , 1976, European journal of biochemistry.

[30]  Hans Lennernäs,et al.  Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[31]  Patrick Poulin,et al.  Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. , 2002, Journal of pharmaceutical sciences.

[32]  Alexander Tropsha,et al.  Quantitative structure-pharmacokinetic parameters relationships (QSPKR) analysis of antimicrobial agents in humans using simulated annealing k-nearest-neighbor and partial least-square analysis methods. , 2004, Journal of pharmaceutical sciences.

[33]  M. Cronin,et al.  Quantitative structure‐pharmacokinetic relationship modelling: apparent volume of distribution , 2004, The Journal of pharmacy and pharmacology.

[34]  B. Barlogie,et al.  Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. , 1989, Blood.

[35]  F. Wingen,et al.  Pharmacokinetics of the osteotropic diphosphonate 3-amino-1-hydroxypropane-1,1-diphosphonic acid in mammals. , 1987, Arzneimittel-Forschung.

[36]  L. H. Hall and L.B. Kier Molecular Connectivity Chi Indices for Database Analysis and Structure-Property Modeling , 2000 .

[37]  R. Benjamin,et al.  Pharmacokinetic and biochemical studies on acivicin in phase I clinical trials. , 1985, Cancer research.

[38]  A. Tsantili-Kakoulidou,et al.  Quantitative structure-pharmacokinetic relationships for disposition parameters of cephalosporins. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[39]  C. Löwik,et al.  The Role of Geranylgeranylation in Bone Resorption and Its Suppression by Bisphosphonates in Fetal Bone Explants In Vitro: A Clue to the Mechanism of Action of Nitrogen‐Containing Bisphosphonates , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[40]  M Danhof,et al.  Multivariate quantitative structure-pharmacokinetic relationships (QSPKR) analysis of adenosine A1 receptor agonists in rat. , 1999, Journal of pharmaceutical sciences.

[41]  Franco Lombardo,et al.  A hybrid mixture discriminant analysis-random forest computational model for the prediction of volume of distribution of drugs in human. , 2006, Journal of medicinal chemistry.

[42]  H. Neu,et al.  Kinetics of mezlocillin and carbenicillin , 1978, Clinical pharmacology and therapeutics.

[43]  S Oie,et al.  Effect of altered plasma protein binding on apparent volume of distribution. , 1979, Journal of pharmaceutical sciences.

[44]  Paul D. Martin,et al.  Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. , 2003, Clinical therapeutics.

[45]  M Paul Gleeson,et al.  In silico human and rat Vss quantitative structure-activity relationship models. , 2006, Journal of medicinal chemistry.

[46]  Marilyn E. Morris,et al.  Prediction of Biliary Excretion in Rats and Humans Using Molecular Weight and Quantitative Structure–Pharmacokinetic Relationships , 2009, The AAPS Journal.

[47]  Franco Lombardo,et al.  In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set. , 2009, Journal of medicinal chemistry.

[48]  H. Hasegawa,et al.  Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[49]  Franco Lombardo,et al.  Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds , 2008, Drug Metabolism and Disposition.